Risk factors

The company completed a fundamental pivot from helium exploration to digital infrastructure and data center development in July 2025. It faces going concern doubts, capital deficits, and new Texas regulatory burdens under Senate Bill 6.

Orchestra BioMed continues to incur mounting net losses with substantial accumulated deficits. Clinical studies for Virtue SAB, AVIM Therapy, CNT-HF, and SirolimusEFR face lengthy regulatory approval risks. Operations depend heavily on attracting specialized personnel and managing IT systems.

Legal claims now explicitly mention lightning or electrical damage to flexible gas piping products. Interest rate language dropped references to ongoing increases. Currency text updated from 2024 to 2025 regarding foreign exchange movements.

Capital runway extends only into the fourth quarter of 2026, creating going concern doubt. Reliance centers on advancing product candidate OKI-219 through Phase 1 trials.

Financial performance surged with net income reaching $146.2 million in 2025.

Top five customers represented 47% of revenue in 2025, showing high concentration.

Oruka Therapeutics advanced its clinical pipeline, updating trial statuses for lead candidates ORKA-001 and ORKA-002 in psoriasis and other indications.

Integration risks from the Codorus Valley Merger were removed after completion.

A preliminary auto-liability settlement increased reserves by $26.5 million and exceeded insurance coverage, materially reducing fourth-quarter 2025 results.

Pioneer Bancorp added risks regarding a $2.0 million goodwill impairment, artificial intelligence adoption, and ongoing fraud and litigation. Insurance carriers denied or conditioned coverage for past fraud claims. The Federal Reserve reduced the federal funds target range to 3.50% to 3.75% by December 31, 2025.

PagerDuty achieved GAAP profitability for the fiscal year ended January 2026, reducing accumulated deficit to $421.8 million.

GrabAGun faces severe regulatory scrutiny regarding ATF compliance and FFL transfers. The business relies heavily on wholesale vendor relationships without long-term contracts. Internal controls suffer from material weaknesses due to insufficient personnel and lack of segregation of duties.